ASH 2015 - Multiple Myeloma

Daratumumab plus Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a 4-Arm Phase 1b Study

ASH 2015 - Multiple Myeloma

Conference Correspondent

Ixazomib plus Lenalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM): Results of the Phase 3 Tourmaline-MM1 Study

ASH 2015 - Multiple Myeloma

Conference Correspondent

Carfilzomib plus Filanesib versus Carfilzomib in Patients with Advanced Multiple Myeloma

ASH 2015 - Multiple Myeloma

Conference Correspondent

Subgroup Analysis of the ENDEAVOR Study of Carfilzomib/Dexamethasone versus Bortezomib/Dexamethasone in Patients with Relapsed MM

ASH 2015 - Multiple Myeloma

Conference Correspondent

Subgroup Analysis Based on Cytogenetic Risk Status: Carfilzomib / Lenalidomide / Dexamethasone versus Lenalidomide / Dexamethasone (ASPIRE Study)

ASH 2015 - Multiple Myeloma

Conference Correspondent

Page 3 of 3

1
2
3